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Background: The treatment of metastatic gastric cancer is not uniform, and the prognostic factors and indications
for surgery are currently unclear. This retrospective study aimed to identify the prognostic factors and clinical
indications for surgery in patients with metastatic gastric cancer.
Methods: A total of 123 consecutive patients with gastric cancer and synchronous distant metastasis treated
between January 1999 and December 2011 were reviewed. Patient, tumor, laboratory, surgical, and chemotherapy
factors were analyzed, with overall survival as the endpoint. Univariate analyses were performed using the log-rank
test, multivariate analyses were performed using the Cox proportional hazards model, and Kaplan-Meier curves were
used to estimate survival. Significance was set at p < 0.05.
Results: The median overall survival time was 13.1 months. Ninety-eight patients received chemotherapy. Twenty-eight
patients underwent gastrectomy with metastasectomy and 55 underwent gastrectomy without metastasectomy. The
median overall survival time for patients who underwent gastrectomy with metastasectomy, gastrectomy without
metastasectomy, and no surgical intervention was 21.9 months, 12.5 months, and 7.2 months, respectively (p < 0.001).
Multivariate analysis identified gastrectomy with or without metastasectomy, performance status (PS) ≥3, neutrophil-
to-lymphocyte ratio (NLR) >3.1, and carbohydrate antigen 19–9 (CA19-9) level >37 U/mL as predictors of poor survival.
NLR and CA19-9 level were also independent prognostic factors in the group of patients who underwent surgery.
Conclusions: High pretreatment NLR, CA19-9 level, and PS are predictors of poor prognosis in patients with metastatic
gastric cancer. In selected patients, gastrectomy can be performed safely, and may be associated with longer survival.Background
Gastric cancer is a major health problem. In 2011,
989,600 new cases and more than 738,000 deaths due to
gastric cancer were predicted worldwide [1]. Metastatic
gastric cancer has a poor prognosis, and the manage-
ment of this disease is not uniform. In early clinical tri-
als, systemic chemotherapy was associated with longer
survival and improved quality of life compared with sup-
portive care alone [2,3]. Currently, the only standard
management to prolong survival in patients with meta-
static gastric cancer is palliative chemotherapy with best
supportive care [4].
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unless otherwise stated.cancer remains unclear. Some studies found that resec-
tion may be beneficial in terms of survival, symptomatic
relief, and quality of life [5-7], whereas other studies re-
ported poor outcomes after resection [8,9]. No random-
ized trials comparing resection with observation or other
management have been reported. Although there is in-
creasing evidence that chemotherapy for metastatic gastric
cancer prolongs survival, the prognosis of metastatic gas-
tric cancer patients who receive only chemotherapy re-
mains poor, with a median overall survival time of about
1 year [10,11].
The aims of this study were to determine the natural
clinical course in patients who have metastatic disease at
the time of diagnosis with gastric cancer, and to determine
the important factors associated with overall survival in
terms of the primary tumor and the metastatic disease.
Patients who underwent gastrectomy with or withouttd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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factors associated with prolonged survival in this group.
Methods
From the prospectively collected database at Mie University
Hospital, 123 consecutive patients who were diagnosed
with metastatic gastric cancer between January 1, 1999
and December 31, 2011 were identified. All patients
presented with synchronous primary and metastatic
disease prior to treatment. Patient details were re-
corded at presentation, during all treatments, and at
follow-up visits until death or November 2013. Patients
who first had metastatic disease diagnosed during
laparotomy were excluded from this study.
The Medical Ethics Committee of Mie University
Graduate School of Medicine approved this retrospective
study. The study was conducted in accordance with the
guidelines of the 1975 Declaration of Helsinki. The need
for informed patient consent was waived because of the
retrospective nature of the study.
The patient characteristics recorded included age, sex,
and Eastern Cooperative Oncology Group performance
status (PS). Primary tumor data collected included the
location of the primary tumor (upper, middle, or lower
stomach), degree of differentiation (well, moderate, or
poorly differentiated), adjacent organ invasion (present
or absent), and bulky perigastric or celiac lymph nodes
(present or absent). Laboratory data collected included
the neutrophil-to-lymphocyte ratio (NLR; defined as ele-
vated if above the median value of 3.1), hemoglobin
(Hb) level (defined as decreased if < 12 g/dL), albumin
(Alb) level (defined as decreased if < 3.5 g/dL), C-reactive
protein (CRP) level (defined as elevated if >0.2 mg/dL),
carcinoembryonic antigen (CEA) level (defined as elevated
if >6 ng/mL), and carbohydrate antigen 19–9 (CA19-9)
level (defined as elevated if >37 U/mL). Metastatic
tumor factors recorded included the number of organs
with metastatic disease and the presence or absence of
metastasis to the liver, peritoneum, distant lymph nodes,
and other organs. NLR was calculated as the neutrophil
count divided by the lymphocyte count. Contrast-enhanced
computed tomography (CT) was performed to evaluate in-
vasion of the primary tumor into adjacent organs, bulky
lymph nodes, and the presence or absence of distant metas-
tasis. Lymph nodes were defined as bulky if an individual
node measured ≥3 cm in diameter.
Gastrectomy with or without metastasectomy was
considered in patients with adequate organ function and
PS ≤ 2. Patients with extensive tumor burden such as ex-
tensive peritoneal metastases were not considered suit-
able for gastrectomy. Patients with severe symptoms
such as obstruction, perforation, or bleeding resulting
directly from the gastric tumor were considered for gas-
trectomy without metastasectomy. When baseline CTfindings suggested that complete resection was technic-
ally feasible, surgery was selected as the initial therapy,
and open laparotomy was performed with the aim of
achieving complete gross resection of the primary and
metastatic tumor. If surgical exploration showed that
complete resection was not feasible, the primary tumor
was resected and chemotherapy was administered. The
extent of surgery was categorized as subtotal gastrec-
tomy, total gastrectomy, extended gastrectomy, or non-
resection. The non-resection group included patients
who underwent gastric bypass surgery, placement of a
feeding jejunostomy tube, and open biopsy. In patients
with liver metastasis, complete gross resection was de-
fined as complete removal of hepatic metastases by sur-
gery or ablation. In patients with peritoneal seeding
classified as P1 (metastases to the adjacent peritoneum,
such as the lesser or greater omentum, but not to the
distant peritoneum) or P2 (a few or several scattered
metastases to the distant peritoneum) according to the
Japanese classification of gastric carcinoma (first English
edition), gross resection was defined as complete resec-
tion of all peritoneal nodules [12]. In patients with intra-
abdominal distant lymph node metastasis, complete gross
resection was defined as lymphadenectomy with tumor-
free surgical margins. Tumor resection without macro-
scopic residual cancer at the time of surgery was classified
as gastrectomy with metastasectomy, and tumor resection
with macroscopic residual cancer was classified as gastrec-
tomy without metastasectomy.
CT for the assessment of treatment response was per-
formed 1 month after the start of chemotherapy and
then every 3 months. Patients were reassessed for the
feasibility of complete surgical resection at each evalu-
ation. Patient survival was determined by follow-up con-
tact by telephone or mail, or by review of the outpatient
records. Patients were followed until death or November
30, 2013. The median follow-up period was 9.3 months.
Statistical analysis
Data are presented as number (percentage). The clinico-
pathological factors of the whole group (n = 123) were
compared with those of the resection group (n = 83)
who underwent gastrectomy with or without metasta-
sectomy. This method was chosen to enable evaluation
of prognostic factors with as complete a denominator as
possible, and to compare the results with patients who
eventually underwent gastrectomy with or without metas-
tasectomy. Patient, tumor, laboratory, and treatment
factors were compared between the resection and non-
resection groups using the χ2 test. The end of the
follow-up period was November 30, 2013, and the me-
dian follow-up period in the resection group was
12.5 months. The beginning of the follow-up period
was defined as the date of diagnosis of metastatic
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time from diagnosis to death regardless of cause, or to
the time of the last follow-up (with or without disease).
Variables were compared between groups by univariate
analyses using the log-rank test, and prognostic factors
associated with survival were identified by multivariate
analysis using the Cox proportional hazards model with
stepwise regression. All analyses were performed using
the SPSS computer software package (Statistical Product
and Service Solutions 20; SPSS Inc., Chicago, IL, USA).
Survival curves were constructed using the Kaplan–Meier
method.
Results
The median survival time of patients with metastatic
gastric cancer was 13.1 months. Table 1 shows the fre-
quency distributions of various clinicopathological fac-
tors in the whole group (n = 123), the resection group
(gastrectomy with or without metastasectomy, n = 83),
and the non-resection group (n = 40), including patient,
primary tumor, metastatic tumor, laboratory, surgery,
and chemotherapy factors.
Whole group
The median age of patients was 66 years (range 18–94
years) and approximately two-thirds of the patients were
male. Ninety patients (73%) died during the follow-up
period, with the majority dying of disease-related causes.
The most common site of metastasis was the periton-
eum (54%), followed by distant lymph nodes (45%) and
the liver (33%). There was metastasis to two or more or-
gans in 40% of patients (Table 1). Among patients who
did not undergo gastrectomy with or without metasta-
sectomy, 6 received best supportive care only, and 34 re-
ceived chemotherapy with or without gastric bypass
surgery and placement of a feeding jejunostomy tube
(see Additional file 1).
Comparisons between the non-resection and resection
groups are shown in Table 1. The non-resection group
had significantly higher PS, higher frequency of adjacent
organ invasion, and higher frequency of distal lymph
node metastasis than the resection group.
Univariate analyses showed that poor survival was
significantly associated with PS 3, NLR >3.1, CRP
level >0.2 mg/dL, Alb level < 3.5 g/dL, CA19-9 level >37
U/mL, adjacent organ invasion, presence of bulky lymph
nodes, metastasis to multiple organs, absence of gastrec-
tomy with or without metastasectomy, and absence of
chemotherapy (Table 2). The CEA level tended to be asso-
ciated with survival, but this association was not signifi-
cant. Multivariate analysis using the Cox proportional
hazards model including the factors associated with sur-
vival on univariate analyses (p < 0.05) identified PS ≤ 2,
NLR ≤ 3.1, and CA19-9 level ≤ 37 U/mL as significantpredictors of longer survival (Table 3). The multivariate
model showed longer survival in the resection group com-
pared with the non-resection group [hazard ratio (HR) =
0.55, 95% confidence interval (CI) 0.32–0.95, p = 0.0033)
(Table 3).
Figure 1 shows that the group who underwent gastrec-
tomy with metastasectomy had the longest overall sur-
vival, followed by the group who underwent gastrectomy
without metastasectomy, and the group who did not
undergo gastrectomy (p < 0.001). The 3-year actuarial
survival rate for gastrectomy with metastasectomy, gas-
trectomy without metastasectomy, and no gastrectomy
was 25.3%, 10.1%, and 0%, respectively. Only patients who
underwent gastrectomy with or without metastasectomy
survived for longer than 5 years. Figure 2 shows the un-
favorable effect of NLR >3.1 (p < 0.001) and Figure 3
shows that CA19-9 level >37 U/mL was associated with
poorer survival (p = 0.003).
Surgery group
Eighty-three patients underwent gastrectomy with or with-
out metastasectomy, of which 47 (57%) underwent total
gastrectomy and 24 (29%) underwent partial gastrectomy.
Twelve patients (14%) underwent en bloc resection of the
tumor with an adjacent organ, most commonly the spleen
or distal pancreas. Thirty-six patients (43%) underwent D2
or more extensive lymphadenectomy. Twenty-eight pa-
tients who underwent metastasectomy, including 2 (7%)
who underwent resection of para-aortic lymph nodes me-
tastasis, 10 (36%) who underwent hepatectomy and/or ab-
lation of hepatic metastasis, and 16 (57%) who underwent
peritonectomy for peritoneal metastasis (Table 1). Postop-
erative complications including wound infection, intra-
abdominal abscess, leakage, and small bowel obstruction
were not severe in most cases, and there were no surgery-
related perioperative deaths.
Twenty-three of the 83 patients (28%) received systemic
chemotherapy prior to surgery, including 15 who received
5-fluorouracil and cisplatin, 6 who received taxane and 5-
fluorouracil, and 2 who received irinotecan and cisplatin.
In these 23 patients, the median time from the diagnosis
of metastatic disease to surgery was 1.9 months (range 1–
13.6 months). Five of these 23 patients underwent planned
gastrectomy without metastasectomy because of gastric
obstruction, bleeding, or perforation. In these five patients,
the median time from diagnosis to surgery was 0.6 months.
In the remaining 18 patients, complete resection was
planned. Thirteen of these 18 patients underwent success-
fully gastrectomy with metastasectomy (complete resec-
tion), and the remaining 5 underwent gastrectomy without
metastasectomy because surgical exploration revealed an
unexpectedly large metastatic tumor burden. In these 18
patients, the median time from diagnosis to surgery was
3.8 months.













≤ 65 57 (46) 37 (45) 20 (50)
0.670
>65 66 (54) 46 (55) 20 (50)
Sex
Female 38 (31) 29 (35) 9 (22)
0.212
Male 85 (69) 54 (65) 31 (78)
PS
0 46 (37) 40 (48) 6 (15)
< 0.001
1 47 (38) 34 (41) 13 (33)
2 20 (16) 9 (11) 12 (30)
3 10 (9) 0 9 (22)
Body mass index
(kg/m2)
≤ 21 62 (50) 41 (49) 19 (47)
0.848
>21 61 (50) 42 (51) 21 (33)
Primary tumor data
Location in stomach
Lower 31 (25) 24 (29) 7 (18)
0.058
Middle 33 (27) 26 (31) 7 (18)
Upper 37 (30) 22 (27) 15 (37)
Whole 22 (18) 11 (13) 11 (27)
Histological
differentiation
Differentiated 45 (37) 33 (40) 12 (30)
0.324
Undifferentiated 78 (63) 50 (60) 28 (70)
Adjacent organ
invasion
Present 32 (26) 11 (13) 21 (52)
< 0.001
Absent 91 (74) 72 (87) 19 (48)
Bulky lymph nodes
Present 75 (61) 46 (55) 21 (52)
0.079
Absent 48 (39) 37 (45) 19 (48)
Laboratory data
CEA (ng/mL)
≤ 6 76 (62) 49 (59) 27 (68)
0.431
>6 47 (38) 34 (41) 13 (32)
CA19-9 (U/mL)
≤ 37 75 (61) 55 (66) 20 (50)
0.114
>37 48 (39) 28 (34) 20 (50)
NLR
≤ 3.1 64 (52) 46 (55) 18 (45)
0.337
>3.1 59 (48) 37 (45) 22 (55)
Table 1 Frequency distributions of clinicopathological
variables (Continued)
Hb (g/dL)
≤ 12 64 (52) 44 (53) 20 (50)
0.114
>12 59 (48) 39 (47) 20 (50)
CRP (mg/dL)
≤ 0.2 58 (47) 44 (53) 14 (35)
0.083
>0.2 65 (53) 39 (47) 26 (65)
Alb (g/dL)
≤ 3.5 50 (41) 29 (35) 21 (52)
0.079




1 74 (60) 53 (64) 21 (52)
0.244
≥2 49 (40) 30 (36) 19 (48)
Peritoneal metastasis
Yes 66 (54) 42 (51) 24 (60)
0.343
No 57 (46) 41 (49) 16 (40)
Distant nodal
metastasis
Yes 55 (45) 30 (36) 25 (62)
0.007
No 68 (55) 53 (64) 15 (38)
Hepatic metastasis
Yes 40 (33) 31 (37) 9 (23)
0.107
No 83 (67) 52 (63) 31 (77)
Surgical data
Metastasectomy
Yes 28 (23) 28 (34) –





Lymph node 2 –
Liver 10 -–
Chemotherapy
Yes 98 (80) 64 (77) 34 (85)
0.349
No 25 (20) 19 (23) 6 (15)
Chemotherapy before
surgery
Yes 23 (28) –
No 60 (72) –
Chemotherapy after
surgery
Yes 64 (77) –
No 19 (23) –
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Table 2 Univariate analyses for overall survival in
metastatic gastric cancer patients (n = 123)
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3 2.4





























Adjacent organ invasion 0.009
Yes 7.8
No 14.6
Table 2 Univariate analyses for overall survival in
metastatic gastric cancer patients (n = 123) (Continued)
Bulky lymph nodes 0.011
Yes 9.3
No 12.5
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http://www.biomedcentral.com/1471-2407/14/409Sixty patients underwent initial surgery for the primary
and metastatic tumors. Of these, 29 underwent planned
gastrectomy without metastasectomy for symptom palli-
ation (obstruction or bleeding). Complete resection was
planned in the remaining 31 patients, who did not have
obvious symptoms caused by the gastric cancer. Fifteen
of these 31 patients (48%) underwent gastrectomy with
metastasectomy, and 16 underwent gastrectomy without
metastasectomy because surgical exploration revealed an
unexpectedly large tumor burden.
All patients who underwent gastrectomy with metasta-
sectomy received postoperative chemotherapy. Nineteen of
the 55 patients who underwent gastrectomy without metas-
tasectomy did not receive postoperative chemotherapy be-
cause of the patient’s decision or decreased organ function.Table 3 Multivariate analysis for overall survival in
metastatic gastric cancer patients (n = 123)
Variable HR 95% CI p value
PS 3 8.69 3.45–21.87 < 0.001
NLR >3.1 2.30 1.44– 3.67 < 0.001
CA19-9 > 37 U/mL 1.77 1.14–2.76 0.012




Figure 1 Overall survival according to surgical procedure (n = 123). Gastrectomy with metastasectomy, n = 28; gastrectomy without
metastasectomy, n = 55; no definitive surgery, n = 40 (p < 0.001).
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gastrectomy with and without metastasectomy was 21.7
and 12.7 months, respectively (Figure 1). Patients who
underwent gastrectomy with metastasectomy had signifi-
cantly longer survival than patients who underwent gas-
trectomy without metastasectomy. Sixty patients (72%)
died during the follow-up period, all from disease-
related causes. Ten of the patients (36%) who underwent
gastrectomy with metastasectomy had no evidence of
tumor recurrence at the time of the last follow-upFigure 2 Overall survival according to neutrophil-to-lymphocyte ratio
patients (p < 0.001).(median follow-up period 29.4 months, range 12.2–
60.2 months). Univariate analyses showed that poor sur-
vival was significantly associated with NLR >3.1, CRP
level >0.2 mg/dL, Alb level < 3.5 g/dL, CEA level >6 ng/mL,
CA19-9 level >37 U/mL, absence of metastasectomy,
and absence of chemotherapy (Table 4). The number of
organs with metastatic disease tended to be associated
with survival, but this association was not significant.
Multivariate analysis using the Cox proportional hazards
model including the factors associated with survival on(NLR) (n = 123). The NLR was at ≤ 3.1 in 64 patients and >3.1 59
Figure 3 Overall survival according to CA19-9 level (n = 123). The CA19-9 level was ≤ 37 U/mL in 75 patients and >37 U/mL in 48 patients (p = 0.003).
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http://www.biomedcentral.com/1471-2407/14/409univariate analyses (p < 0.05) identified NLR >3.1 (HR =
2.11, 95% CI 1.06–4.22, p = 0.034), and CA19-9 level ≤ 37
U/mL (HR = 2.31, 95% CI 1.22–4.36, p = 0.010) as signifi-
cant predictors of longer survival (Table 5).
Discussion
The results of this study demonstrate that gastrectomy
with or without metastasectomy prolongs survival in a
highly selected group of patients with metastatic disease
at the time of presentation with gastric cancer, compared
with patients who do not undergo surgical intervention.
Many previous studies have evaluated surgical resection
for metastatic gastric cancer, but this study evaluated
surgical intervention specifically in patients with meta-
static disease at the time of presentation, compared with
patients at the same institution who either were not re-
ferred for surgical resection or were evaluated but were
not considered to be suitable for surgical resection. Un-
derstanding that there is a selection bias, comparison of
the survival curve of the non-surgical group (patients
who were not candidates for surgical intervention and
patients who may have been surgical candidates but
were not offered surgery) with the survival curve of the
surgical group suggests that surgical intervention has a
favorable effect on survival. In our entire cohort, the fac-
tors identified as predictors of longer survival on multi-
variate analysis were PS ≤ 2, NLR ≤ 3.1, gastrectomy
with or without metastasectomy, and CA19-9 level ≤ 37
U/mL. Separate analysis of the surgical group showed
that NLR and CA19-9 level were the most important
factors associated with survival in this group.
Generally, the reasons for performing gastrectomy with
or without metastasectomy in gastric cancer patients withdistant metastasis are: (1) primary tumor resection to
relieve potentially life-threatening symptoms such as
obstruction, perforation, or bleeding; (2) increased re-
sponsiveness of the residual tumor to adjuvant treat-
ment after removal of a significant proportion of the
tumor load; and (3) potential immunological benefits
because of reduction of immunosuppressive cytokines
produced by the tumor [13-15]. Gastrectomy is the pro-
cedure of choice in selected patients, even though it has
never been compared with observation in a randomized
trial. Multiple previous studies reported that gastrectomy
with or without metastasectomy prolonged survival in pa-
tients with metastatic gastric cancer [16,17]. In our study
group, the indications for surgical intervention were: (1)
adequate organ function and acceptable PS, (2) absence of
extensive invasion of the primary tumor into adjacent or-
gans, and (3) absence of extensive metastatic tumor. Our
results are in general agreement with those of previously
reported studies, suggesting that our indications for sur-
gery are feasible, and that surgical intervention is benefi-
cial for patients with metastatic gastric cancer.
Over the past few decades, several studies have
attempted to identify the prognostic factors in patients
with metastatic gastric cancer. In general, it is thought
that greater residual tumor load and higher PS nega-
tively affect prognosis. However, the associations be-
tween prognosis and pretreatment laboratory data have
not been fully determined. This study identified pretreat-
ment NLR and CA19-9 level as prognostic factors in pa-
tients with metastatic gastric cancer. CEA and CA19-9
levels reflect tumor biology and are commonly used
markers for gastric cancer [18]. CA19-9 may play a role
in the adhesion of cancer cells to endothelial cells,
Table 4 Univariate analyses for overall survival in
metastatic gastric cancer patients who underwent




































Adjacent organ invasion 0.364
Yes 13.1
No 16.2






Table 4 Univariate analyses for overall survival in
metastatic gastric cancer patients who underwent
surgery (n = 83) (Continued)
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http://www.biomedcentral.com/1471-2407/14/409resulting in hematogenous metastasis [19]. Immunohis-
tochemical examination showed marked expression of
CA19-9 in gastric cancer tissue [20]. One study reported
that CEA and CA19-9 levels were associated with prog-
nosis in patients with gastric cancer who had undergone
curative resection [21]. Another study found that ele-
vated CA19-9 levels in gastric cancer patients were well
correlated with various types of metastasis [22]. This
study identified a high pretreatment CA19-9 level as an
independent prognostic factor. On the other hand, it is
increasingly recognized that clinical outcomes in cancer
patients are influenced not only by the oncological char-
acteristics of the tumor, but also by host-response fac-
tors. It has been suggested that NLR (calculated as
neutrophil count divided by lymphocyte count), CRP
level, and albumin level reflect host-response factors in
various solid tumors including gastric cancer. This study
found that an elevated NLR was an independent prog-
nostic factor in patients with metastatic gastric cancer.
Interestingly, NLR and CA19-9 level were independent
prognostic factors both in the overall group of patientsTable 5 Multivariate analysis for overall survival in
metastatic gastric cancer patients who underwent surgery
(n = 83)
Variable HR 95% CI p value
NLR >3.1 3.16 1.81–5.51 < 0.001
CA19-9 > 37 U/mL 2.65 1.55–4.52 < 0.001
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who underwent surgical resection. We therefore suggest
that the pretreatment NLR and CA19-9 level can be used
to select patients who are suitable for surgery.
Local treatment modalities such as gastrectomy,
metastasectomy, ablation therapy, or a combination of
these may effectively manage tumor burden. However,
many clinicians have concerns about the detrimental ef-
fects of surgery in patients with metastatic gastric can-
cer. Even in large volume centers, gastrectomy for
metastatic gastric cancer has been reported to be associ-
ated with high rates of morbidity (>50%) and mortality
(6–12%) [7,23]. Some recent studies [24,25] reported ac-
ceptable postoperative morbidity and mortality rates. In
this study, severe postoperative morbidity was uncom-
mon and there were no surgery-related perioperative
deaths. The results of some previous studies and of this
study therefore indicate that gastrectomy with or with-
out metastasectomy can be safely performed at institutes
with appropriate experience.
Previous studies [10,11] reported that systemic chemo-
therapy improves survival, and chemotherapy has there-
fore been the mainstay of treatment for metastatic
gastric cancer. However, there is ongoing controversy re-
garding the usefulness of surgical resection for meta-
static gastric cancer, the indications for surgery, and the
type of surgery that should be performed. A previous
study that reported good outcomes after surgical resec-
tion, including good survival outcomes, was limited by
the selection of patients with less severe disease for sur-
gical resection. The current study therefore made an ef-
fort to eliminate selection bias. First, preoperative CT
findings were reviewed to determine the preoperative
stage of all patients. Second, patients were stratified ac-
cording to the presence or absence of chemotherapy. Al-
though chemotherapy was found to be significantly
associated with prognosis in the whole group on univariate
analysis, it was not found to be an independent prognostic
factor on multivariate analysis. The prognostic effect of
chemotherapy was therefore minimal in this study.
Although the role of metastasectomy is well established
for colorectal cancer and sarcoma, there is still contro-
versy regarding the usefulness of surgery targeting meta-
static lesions in patients with gastric cancer, who have a
reported median survival time of 11.2–31.0 months
[24,26]. Some non-randomized comparative analyses sug-
gested that aggressive surgical treatment of patients with
metastatic gastric cancer prolongs survival. However,
metastatic gastric cancer encompasses a heterogeneous
patient population in which both palliative and curative
treatment strategies may be used. In the current study, pa-
tients who underwent gastrectomy with metastasectomy
had a much longer survival time than patients who under-
went gastrectomy without metastasectomy. Although only28 patients underwent gastrectomy with metastasectomy,
this included 13 patients who initially had an unresectable
tumor burden. The data from this study suggest that gas-
trectomy with metastasectomy may improve outcomes
patients with metastatic gastric cancer selected according
to the NLR and CA19-9 level.
In this study, patients who underwent tumor resection
had significantly longer survival times than those who
did not. However, this result must be interpreted with
caution because of the retrospective nature of the study
and the differences in patient characteristics between the
two groups. Decisions regarding suitability for resection
are strongly influenced by invasion of neighboring or-
gans, the number of organs with metastasis, and PS. In
this study, patients who underwent gastrectomy with or
without metastasectomy had a better PS and were more
likely to have no neighboring organ invasion than pa-
tients who did not undergo gastrectomy. It has been
suggested that this selection bias is the most important
contributor to the difference in survival between the two
groups. Although the depth of invasion and the number
of organs with metastasis were not found to be inde-
pendent predictors of survival on multivariate analysis,
the survival benefit from gastrectomy with or without
metastasectomy should be further evaluated by stratified
analysis. Recently, prospective randomized trials (the
Japan Clinical Oncology Group [JCOG] 0705 and Korea
Gastric Cancer Association [KGC] A01 and GYMSA trials)
were initiated to evaluate the role of debulking gastrectomy
in patients with metastatic gastric cancer [27,28]. These
randomized trials are expected to clarify the role of debulk-
ing gastrectomy in this patient population.
Conclusions
The results of this study show that gastrectomy with or
without metastasectomy for gastric cancer can be per-
formed safely and is associated with longer survival com-
pared with a nonrandomized control group treated during
the same period at the same institution. It is not known
whether this is due to differences in PS or disease burden
between the two patient groups. A prospective randomized
trial could help to determine whether gastrectomy should
be considered in selected patients with metastatic gastric
cancer. Surgeons should carefully consider surgical inter-
vention in patients with an elevated NLR or CA19-9 level,
because these patients have a poor prognosis with or with-
out surgical intervention. Evaluation of novel combinations
of resection, local ablation, and chemotherapy should also
continue. Gastrectomy with or without metastasectomy,
performed safely and in addition to other available treat-
ments, is an important aspect of the multidisciplinary man-
agement of patients with metastatic gastric cancer. A
larger prospective trial is needed to further evaluate sur-
gery for the treatment of metastatic gastric cancer.
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Additional file 1: Evaluation and treatment flow in 123 metastatic
gastric cancer patients. Twenty-nine patients underwent gastrectomy
without metastasectomy for symptom palliation. Thirty-one patients were
initially judged to have resectable disease. Twenty-three of the 63 patients
who were initially judged to have unresectable disease underwent
gastrectomy with or without metastasectomy after chemotherapy.
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